The rise of Sildenafil initially fueled a period of growth for the drug industry, however recent shifts present a uncertain picture for shareholders. Generic versions are eating into profits, and continued litigation https://kalefnrw761708.digiblogbox.com/65575661/the-blue-pill-and-pharma-a-risky-investment